deletions | additions       diff --git a/Method.tex b/Method.tex  index c76b1bb..9c98922 100644  --- a/Method.tex  +++ b/Method.tex 
...
\subsection{Sample preparation}  Ranibizumab and bevacizumab solutions were dialysed twice against phosphate buffered saline (PBS) pH 7.4 using D-Tube Midi Dialyzer units from Novagen (6-8~kD cut-off). Subsequently, the purity of the dialysed proteins was checked by standard SDS-PAGE. The proteins were then conjugated to the fluorophore dye  Bis(2,2′-bipyridine)-4′-methyl-4-carboxybipyridine-ruthenium N-succinimidyl ester-bis(hexafluorophosphate) (synonym, Ru(bpy)$_2$(mcbpy-O-Su-ester)(PF$_6$)$_2$, Sigma-Aldrich) by using a succinimidyl ester-modified fluorophore with a short linker (Invitrogen, F6130). Conjugation reactions were performed in PBS adjusted with bicine buffer to pH 8.6 at 2~mg/ml protein concentration with the activated fluorophore ester being used in excess. The reaction was stopped after two hours and conjugated proteins were separated from remaining free dye by size exclusion chromatography (7~kD cut-off; Thermo Fisher). Using this method we generated ranibizumab conjugated to dye with a dye:protein ratio of 1.1:1 and bevacizumab with a dye:protein ratio of 1.3:1. Azide (2.0~mM) was added to all fluorophore-conjugated dye-conjugated  drugs to protect them from microbial deterioration. *** Add Eylea and BSA *** 
...
\subsection{Calculation of hydrodynamic radii}  The anisotropies were calculated from the phosphorescence  intensitytime  decays measured in parallel and perpendicular polarisation directions with eq~\ref{eq:anisotropy} (see Fig~\ref{fig:setup}b,c). The anisotropies contain a fast component in addition of the expected longer component and were fitted with gnuplot to a double-exponential function: \begin{equation}  y = A_1\cdot e^{-\frac{t}{\phi_1}} + A_2\cdot e^{-\frac{t}{\phi_2}} \label{eq:2expfit}  \end{equation}